AGP Limited, a pharmaceutical company, in its Board of Directors meeting held on August 2nd 2018, finalized its financial statements for the half-year ended June 30, 2018.
Compared to the half year ending June 30, 2017, the company’s sales increased by 22.34% while its cost of sales increased by 37.03%, leading to growth in the gross profit of about 12.53%.
While administrative expenses remained about the same as last year, its marketing and selling expenses jumped by 24.53% while other expenses similarly witnessed an increase of 36.9%.
Other income, however, fell by 31.91%, which combined with the increase in its cost of sales, lead to an operating profit growth of just 4.49% despite the significant sales growth.
The company’s finance costs however fell by a noteworthy 94.77%, leading to its profit before taxation growing by 17.59%. Net profit after taxation however grew by 12.12% owing to the 59.89% increase in the company’s taxation over the year.
The company declared an Earning per share of Rs 2.24, 12.56% less than the Rs 2.15 EPS a year ago.
Profit and Loss Account for the Half Year Ending on June 30th 2018
